Ceretek

CereTek is a preclinical-stage biotechnology company focused on developing first-in-class small molecule therapeutics for neurological and psychiatric disorders. The company specializes in the modulation of the NMDA receptor, with a particular emphasis on the GluN2B subunit to address unmet needs in depression and neurodegeneration. CereTek utilizes advanced medicinal chemistry and structure-based design to develop highly selective candidates intended to minimize off-target effects. Led by a team of experienced neuroscience researchers, the company aims to transform the treatment landscape for CNS diseases. Their pipeline currently includes programs targeting treatment-resistant depression and Parkinson's disease.